Literature DB >> 20519840

A 28-day oral toxicity study of fermentation-derived cellulose, produced by Acetobacter aceti subspecies xylinum, in F344 rats.

Akihiro Hagiwara1, Norio Imai, Masashi Sano, Mayumi Kawabe, Seiko Tamano, Satoshi Kitamura, Toshio Omoto, Iwao Asai, Kazuo Yasuhara, Shim-Mo Hayashi.   

Abstract

This study was designed to evaluate any adverse effect of fermentation-derived cellulose, produced by Acetobacter aceti subspecies xylinum, when administered to both sexes of F344 rats at dietary levels of 0, 1.25, 2.5, and 5.0% for 28 days. The treatment had no adverse effects on clinical signs, mortality, body weights and food and water consumption, or on urinalysis, ophthalmology, hematology, blood biochemistry, and histopathology findings. At necropsy, slight increased absolute and relative cecum weights, evident in females ingesting 2.5% and 5.0% dietary levels, were considered to be a physiological adaptation to the poorly absorbed fermentation-derived cellulose. The non-observed-adverse-effect level (NOAEL) from the present study was concluded to be 5.0% in the diet (5,331 mg/kg body weights/day for males, and 5,230 mg/kg body weights/day for females).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20519840     DOI: 10.2131/jts.35.317

Source DB:  PubMed          Journal:  J Toxicol Sci        ISSN: 0388-1350            Impact factor:   2.196


  3 in total

Review 1.  A Review on the toxicology and dietetic role of bacterial cellulose.

Authors:  Fernando Dourado; Miguel Gama; Ana Cristina Rodrigues
Journal:  Toxicol Rep       Date:  2017-09-25

2.  A 90-day dietary study with fibrillated cellulose in Sprague-Dawley rats.

Authors:  Kimberly J Ong; James D Ede; Cassidy A Pomeroy-Carter; Christie M Sayes; Marina R Mulenos; Jo Anne Shatkin
Journal:  Toxicol Rep       Date:  2020-01-20

3.  Ninety-Day Oral Toxicity Assessment of an Alternative Biopolymer for Controlled Release Drug Delivery Systems Obtained from Cassava Starch Acetate.

Authors:  Douglas Rossi Jesus; Lorena Neris Barbosa; Thiago Bruno Lima Prando; Leonardo Franco Martins; Francielli Gasparotto; Karla Moraes Rocha Guedes; Douglas Cardoso Dragunski; Emerson Luiz Botelho Lourenço; Paulo Roberto Dalsenter; Arquimedes Gasparotto Junior
Journal:  Evid Based Complement Alternat Med       Date:  2015-09-14       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.